Search results
90 Results for 'Immune Engineering'
- Technologies (11)
- Collaborations (1)
- Team (0)
- News (59)
- Pages (0)
- Multimedia (19)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 11
-
Metabolically Labeled CAR-T Cells Against Cancer
Through a simple and effective metabolic labeling approach, patient-derived T cells engineered to carry immune-enhancing cytokines on their surfaces could help expand adoptive T cell therapies to treatment of solid tumors and improve blood cancer therapies. -
DoriVac: Boosting Antigen-specific Immune Responses with DNA Origami-Based Vaccines
Personalized cancer and infectious disease vaccine platform harnessing DNA nanotechnology to control the co-delivery and co-presentation of tumor antigen and adjuvant ligands to immune cells with nanoscale precision. This approach has potential to trigger enhanced immune responses against tumors and infectious pathogens. -
SomaCode: Getting Cell Therapies Where They Need to Go
SomaCode is solving the problem of cell therapy delivery by identifying unique molecular “zip codes” for disease and engineering cells to home to those zip codes, making cell therapies safer and more effective. -
Immunostimulatory RNA Therapeutic for Treatment of Infectious Disease and Cancer
Our novel dsRNAs stimulate the immune system to inhibit cancer, bacterial, and viral infections including SARS-CoV-2 and multiple influenza strains. -
Cellular “Backpacks” to Slow Tumor Growth
A cell therapy innovation that keep macrophages activated against cancer. Macrophages are like little soldiers in our bodies that help fend off diseases like cancer. Our cellular “backpacks” are disc-shaped nanoparticles that can stick to a macrophage without being engulfed, and release a steady stream of cytokines into their macrophage “hosts” to help them fight against cancer. -
OMNIVAX: Broadly Deployable Infection Vaccine Platform
OMNIVAX is an immuno-material-based vaccine platform technology able to create safe and effective therapeutic and prophylactic vaccines against viral and bacterial threats. Its modular approach enables the rapid creation of vaccines for pathogens using known and unknown antigens. Current approaches include vaccines against some viral diseases.
Collaborations 1
i3 Center: Biomaterials to Create T Cell ImmunityNews 59
Multimedia 19
-
Video/AnimationHow can we train the immune system to fight cancer?The implantable cancer vaccine is a biomaterial that recruits and reprograms a patient’s own immune cells on-site to kill cancer cells. This revolutionary immuno-material technology was tested in a Phase I clinical trial with promising results and is currently licensed by Novartis as an immunotherapy to treat specific tumor types. Credit: Wyss Institute at Harvard... -
Video/AnimationMetabolic T cell Labeling: simple and effective enhancement of therapeutic T cells with immune-stimulating cytokinesThis animation shows how the surface of patient-derived T cells is metabolically labeled with azido-sugar molecules that then can be used to attach immune-enhancing cytokines with the help of click chemistry. The approach could help expand adoptive T cell therapies to treatment of solid tumors. Credit: Wyss Institute at Harvard University
-
Video/AnimationEliminating brain cancer at its source | Natalie Artzi | TEDxMITGlioblastoma is a lethal, aggressive brain cancer with a dismal median overall survival rate of 15 months, a number that has remained unchanged for decades. Treatment for this devastating disease involves surgical resection followed by chemotherapy and radiation therapy; however, tumor recurrence is inevitable as it is impossible to eliminate all tumor cells with current... -
Video/AnimationSomaCode: GPS for Cell TherapyJust like zip codes help drivers navigate to specific addresses using a GPS system, the molecular ‘zip codes’ identified via the SomaCode platform can be used to deliver cell therapies to their specific targets in the human body, increasing the therapies’ efficacy and reducing side effects. Credit: Wyss Institute at Harvard University -
Audio/PodcastImmunoengineering with Dave Mooney – BIOS PodcastWyss Core Faculty member Dave Mooney is a leader in the fields of biomaterials, mechanotransduction, drug delivery, tissue engineering and immunoengineering. He is interested in understanding how cells sense signals in their environment and how this alters cell behavior. His laboratory develops biomaterials that exploit these signals to regulate specific cells and their function. They... -
Video/AnimationOMNIVAX: Infection Vaccine PlatformThis video explains how OMNIVAX – an immuno-material-based vaccine technology can be used to rapidly create injectable vaccines against diverse viral and bacterial pathogens, and how the platform is used by the team to develop a vaccine against recurring urinary tract infections (UTIs) in their lead human application. Credit: Wyss Institute at Harvard University.